Ann: Investor Presentation, page-7

This is also the first time NXS has admitted 3M took the global distributorship to nobble sales of BlastX rather than to increase them..

“Failed partnership with 3M – product portfolio conflicts and only offered in restricted sites of service”

The large upfront payment from 3M to acquire those rights added largely to early revenue at NXS... It will be interesting to see how the sales trajectory develops from here?

And looking at those ulcer healing pictures in the presentation makes me wish NXS was approved to deliver treatment to aged care homes in Australia given the high prevalence of ulcers suffered by residents and the $10 billion aged care package expected in tomorrow night’s budget.

cheers